BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36208246)

  • 1. [Expression of TCF3 in Burkitt's Lymphoma and Its Proliferative Effect and Prognostic Significance].
    Dong LH; Huang JJ; Liu J; Gao X; DU JW; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1435-1439. PubMed ID: 36208246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.
    Dong L; Huang J; Zu P; Liu J; Gao X; Du J; Li Y
    Bioengineered; 2021 Dec; 12(1):7995-8005. PubMed ID: 34658308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burkitt lymphoma-related
    Yamazaki T; Liu L; Conlon EG; Manley JL
    RNA Biol; 2020 Oct; 17(10):1383-1390. PubMed ID: 32449435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
    Schmitz R; Young RM; Ceribelli M; Jhavar S; Xiao W; Zhang M; Wright G; Shaffer AL; Hodson DJ; Buras E; Liu X; Powell J; Yang Y; Xu W; Zhao H; Kohlhammer H; Rosenwald A; Kluin P; Müller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Ogwang MD; Reynolds SJ; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pittaluga S; Wilson W; Waldmann TA; Rowe M; Mbulaiteye SM; Rickinson AB; Staudt LM
    Nature; 2012 Oct; 490(7418):116-20. PubMed ID: 22885699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study.
    Man J; Wang H; Qian X; Chen L; Ma Y; Qian M; Zhai X
    Leuk Lymphoma; 2022 Oct; 63(10):2453-2460. PubMed ID: 35617527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.
    Preudhomme C; Dervite I; Wattel E; Vanrumbeke M; Flactif M; Lai JL; Hecquet B; Coppin MC; Nelken B; Gosselin B
    J Clin Oncol; 1995 Apr; 13(4):812-20. PubMed ID: 7707106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
    Nomura Y; Yoshida S; Karube K; Takeshita M; Hirose S; Nakamura S; Yoshino T; Kikuchi M; Ohshima K
    Cancer Sci; 2008 Aug; 99(8):1564-9. PubMed ID: 18754867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.
    Rapoport AP; Simons-Evelyn M; Chen T; Sidell R; Luhowskyj S; Rosell K; Obrig T; Hicks D; Hinkle PM; Nahm M; Insel RA; Abboud CN
    Blood Cells Mol Dis; 2001; 27(3):610-24. PubMed ID: 11482875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
    Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
    Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
    Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
    Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience].
    Baryakh EA; Tyurina NG; Vorobyev VI; Gemdzhyan EG; Mangasarova YK; Klyasova GA; Kovrigina AM; Obukhova TN; Zvonkov EE; Vernyuk MA; Chervontseva AM; Polyakov YY; Misyurina АЕ; Valiev TT; Zherebtsova VA; Magomedova AU; Galstyan GM; Yatskov KV; Nesterova ES; Vorobyev AI; Kravchenko SK
    Ter Arkh; 2015; 87(7):4-14. PubMed ID: 26390720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
    Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary ovarian Burkitt's lymphoma: a rare oncological problem in gynaecology: a review of literature.
    Stepniak A; Czuczwar P; Szkodziak P; Wozniakowska E; Wozniak S; Paszkowski T
    Arch Gynecol Obstet; 2017 Oct; 296(4):653-660. PubMed ID: 28770352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.
    Matou-Nasri S; Rabhan Z; Al-Baijan H; Al-Eidi H; Yahya WB; Al Abdulrahman A; Almobadel N; Alsubeai M; Al Ghamdi S; Alaskar A; AlBalwi M; Alzahrani M; Alabdulkareem I
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):239-252. PubMed ID: 27641442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ultrastructural morphometric and immunophenotypic evaluation of Burkitt's and Burkitt's-like lymphomas.
    Payne CM; Grogan TM; Cromey DW; Bjore CG; Kerrigan DP
    Lab Invest; 1987 Aug; 57(2):200-18. PubMed ID: 3497304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
    Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
    J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines.
    Koch A; Jeiler B; Roedig J; van Wijk SJL; Dolgikh N; Fulda S
    Neoplasia; 2021 May; 23(5):539-550. PubMed ID: 33971465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.
    Rohde M; Bonn BR; Zimmermann M; Lange J; Möricke A; Klapper W; Oschlies I; Szczepanowski M; Nagel I; Schrappe M; ; ; Loeffler M; Siebert R; Reiter A; Burkhardt B
    Haematologica; 2017 Jun; 102(6):1091-1098. PubMed ID: 28209658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.